Last updated: February 27, 2026
What is NDC 68084-0354?
NDC 68084-0354 corresponds to Humira (adalimumab) injection, a biologic drug primarily prescribed for autoimmune diseases including rheumatoid arthritis, Crohn’s disease, and psoriatic arthritis. As of 2023, it remains one of the world's top-selling biologics with significant market presence.
Market Landscape
Current Market Position
Humira (adalimumab) maintained its status as the best-selling drug globally until biosimilar versions entered the market. In 2022, Humira's global sales exceeded $20 billion, driven mainly by North America and Europe. Patent exclusivity in the U.S. ended in 2023, opening the market to biosimilar competition.
Biosimilar Competition
Following patent expiration, biosimilars entered the U.S. market substantially reducing price points and capturing market share:
- Amjevita (Amgen) launched early 2023.
- Other biosimilars, including Cyltezo (AbbVie), entered soon after.
- Biosimilars typically price 15-35% lower than original biologics, impacting revenue streams.
Market Drivers and Challenges
- Drivers: Increased prevalence of autoimmune diseases, patent expiry, cost-containment efforts, and physician acceptance of biosimilars.
- Challenges: Physician bias toward originator brands, regulatory hurdles, and supply chain complexities.
Price Trends & Projections
Historical Pricing
- Pre-biosimilar launch (2022): Average wholesale price (AWP) per 40 mg/0.8 mL syringe ranged between $5,000 and $5,300.
- Post-biosimilar entry (2023): Prices declined to approximately $3,500–$4,200 per syringe, depending on the biosimilar.
Current Market Pricing
| Price Metric |
2022 |
2023 (Post-Biosimilars) |
| Wholesale Price (per syringe) |
~$5,200 |
~$3,800 |
| Average Reimbursed Price |
~$4,800 |
~$3,500 |
| List Price (retail) |
~$5,300 |
~$4,000 |
Volume & Revenue Outlook
- 2023: Biosimilar uptake expected at 35-45% in the U.S., reducing Humira sales by an estimated 40-50% from peak levels.
- 2030 projections: Revenue for adalimumab products could decline by 50-70% from peak, with total sales estimated at $8-10 billion globally.
Price Projection (2024-2026)
| Year |
Projected Average Price (per syringe) |
Key Influences |
| 2024 |
~$3,200–$3,600 |
Biosimilar expansion, price competition stabilizes; potential new indications. |
| 2025 |
~$3,000–$3,400 |
Market saturation, pressure on originator pricing persists. |
| 2026 |
~$2,800–$3,200 |
Increased biosimilar proliferation, possible price compression. |
Key Factors Impacting Price
- Regulatory approval of additional biosimilars.
- Patient access initiatives by payers.
- Manufacturing and supply chain efficiency.
- Market penetration of new formulations or indications.
Future Market Strategies
- Pricing strategies: Biopharma companies will likely adopt tiered pricing, rebates, and tiered access models to maintain revenue.
- Product innovation: Development of subcutaneous or longer-acting formulations may influence pricing.
- Market expansion: Entry into emerging markets could stabilize some revenue streams despite price erosion.
Summary
The price of NDC 68084-0354 (Humira) has declined sharply since biosimilar entry. Market share shifts are expected to continue constraining prices through 2026, with average prices projected to settle around $2,800 to $3,200 per syringe. Long-term revenue will decline by over 50% from peak levels, though overall global biologics sales remain robust due to increasing autoimmune disease prevalence.
Key Takeaways
- Patent expiration in 2023 facilitated biosimilar entry, resulting in immediate price reductions.
- Prices are expected to stabilize around 2024-2026 at approximately $3,000–$3,600 per syringe.
- Biosimilar competition is likely to intensify, driving further price compression.
- Market growth in emerging regions may offset revenue losses in mature markets.
- Development of innovative formulations and indications remains a strategic focus for maintaining profitability.
FAQs
1. How does biosimilar entry impact the pricing of adalimumab?
Biosimilars typically price 15-35% lower than the originator, leading to immediate reductions upon market entry and continued pressure on the original biologic's pricing.
2. What are the main factors influencing future adalimumab prices?
Market saturation with biosimilars, regulatory approvals, payer strategies, and innovation in formulation drive future prices.
3. Will the revenue from Humira ever recover to pre-2023 levels?
Unlikely; biosimilar competition will keep prices and revenue below peak levels observed before patent expiry.
4. How do regional differences affect adalimumab pricing?
Pricing varies significantly; in Europe, prices are generally lower due to national pricing negotiations, while in the U.S., rebates and insurance policies influence actual costs.
5. What is the outlook for new indications of adalimumab?
New indications could bolster sales temporarily, but biosimilar competition will still impact long-term pricing and revenue.
References
[1] IQVIA. (2022). Global Medicines Data.
[2] FDA. (2023). Biosimilar Approval List.
[3] EvaluatePharma. (2023). World Preview 2023, Outlook to 2028.
[4] Transparency Market Research. (2023). Biologics Market Forecast.
